Chem-structure (Edaravone 01)
Edaravone Injection
Product Images NDC 0781-3527
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Edaravone (NDC 0781-3527). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Sandoz Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure-1 (Edaravone 02)
This text provides information related to a comparison study between Edaravone injection and Placebo for ALS (Amyotrophic Lateral Sclerosis) patients. The study evaluates the change in ALSFRS-R (Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised) at Week 24, suggesting that the effectiveness of Edaravone injection is being compared to the placebo in improving the condition of ALS patients.*
Carton (Edaravone 03)
This is a description of Edaravone Injection, a medication with the NDC 0781-3527-20, manufactured by Sandoz. Each 100 mL bag contains 30 mg of edaravone, with other inactive ingredients added for stability and pH adjustment. It is a sterile solution for intravenous infusion, to be administered over a 30-minute period. The package insert provides detailed information on dosage and administration. It is a single-dose medication, and any unused portion must be discarded. The storage instructions include keeping it at 20° to 25°C (68° to 77°F) and protecting it from light. The caution advises against swallowing, and if leaks are found, the bag should be discarded to maintain sterility.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
